<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154444">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089361</url>
  </required_header>
  <id_info>
    <org_study_id>2009-P-000259</org_study_id>
    <nct_id>NCT01089361</nct_id>
  </id_info>
  <brief_title>Immunomodulatory Properties of Ketamine in Sepsis</brief_title>
  <official_title>Immunomodulatory Properties of Ketamine in Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the effect of short-term infusion of ketamine at analgesic
      dosage on the immune response, morbidity and mortality among patients suffering from septic
      shock. We hypothesize that ketamine will modulate the cytokine response to sepsis and reduce
      morbidity and mortality.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum levels of IL-6, IL-10 and TNFα and other cytokines</measure>
    <time_frame>first 7 days of admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects attributable to ketamine</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failures</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of new organ failure as detected by Sequential Organ Failure Assessment [SOFA] score. Definitions are as follows. Central nervous system: delirium, coma, uncontrollable seizures, ICP&gt;20cm H2O Cardiac: MAP &lt;60mmHg, blood pressure supported with pressors, 50 &gt; HR &gt; 120 Respiratory: vented, RR&gt;30, PaO2&lt;60, PaCO2 &gt; 55, Sat&lt;92% Kidney: RIFLE criteria Anemia: Hct&lt;27, transfusion of PRBC Thrmobocytopenia: platelet &lt; 50k, platelet transfusion Liver: biopsy, ALT&gt;200, AST&gt;200, t.bil&gt;2.0, ALP&gt;300 Coaugulation failure: INR&gt;2 if no anticoagulation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Acute Physiology and Chronic Health Evaluation (APACHE) scores</measure>
    <time_frame>7 days</time_frame>
    <description>Difference in average APACHE-II score between the intervention and placebo groups. The point score is calculated from 12 routine physiological measurements (such as blood pressure, body temperature, heart rate etc.) during the first 24 hours after admission, information about previous health status and some information obtained at admission (such as age).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of intensive care unit (ICU) stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline placebo</intervention_name>
    <description>The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients meeting the ACCP/ SCCM definition of severe sepsis will be enrolled in the
             study. These patients should have a known or suspected source of infection.

          -  Patients within 12 hours of the development of one or more organ dysfunctions

          -  Patients must exhibit 3 or more of the following signs of clinical inflammation:

               -  Core temperature &lt; 36ºC or &gt; 38ºC.

               -  Heart rate of 90 or greater not explained by another medical condition.

               -  A respiratory rate of &gt; 20 min-1, a PaCO2 &lt; 32min-1 or the need for mechanical
                  ventilation.

               -  A white blood cell count of &lt; 4000 cell/ml or &gt; 12000 cells/ml or a WBC showing
                  greater then 10% immature neutrophils.

        Exclusion Criteria:

          -  pregnant

          -  increased intracranial pressure or closed head injury

          -  history of psychotic mental disease

          -  receiving Continuous Veno - Venous Hemofiltration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Talmor, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Calandra T, Bochud PY, Heumann D. Cytokines in septic shock. Curr Clin Top Infect Dis. 2002;22:1-23. Review.</citation>
    <PMID>12520644</PMID>
  </reference>
  <reference>
    <citation>Laudanski K, Miller-Graziano C, Xiao W, Mindrinos MN, Richards DR, De A, Moldawer LL, Maier RV, Bankey P, Baker HV, Brownstein BH, Cobb JP, Calvano SE, Davis RW, Tompkins RG. Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15564-9. Epub 2006 Oct 10.</citation>
    <PMID>17032758</PMID>
  </reference>
  <reference>
    <citation>Kawasaki T, Ogata M, Kawasaki C, Ogata J, Inoue Y, Shigematsu A. Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro. Anesth Analg. 1999 Sep;89(3):665-9.</citation>
    <PMID>10475301</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 19, 2010</lastchanged_date>
  <firstreceived_date>March 12, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Daniel Talmor, MD, MPH</name_title>
    <organization>Beth Israel Deaconess Medical Center</organization>
  </responsible_party>
  <keyword>systemic inflammatory syndrome</keyword>
  <keyword>sepsis syndrome</keyword>
  <keyword>septic shock</keyword>
  <keyword>Cytokine</keyword>
  <keyword>Ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
